(Q36111217)

12 August 2017

1 reference

title

Optimal management of the T1G3 bladder cancer (English)

1 reference

12 August 2017

Murugesan Manoharan

1

1 reference

PubMed ID

15862611

12 August 2017

Mark S Soloway

series ordinal

2

1 reference

12 August 2017

1 May 2005

1 reference

Urologic Clinics of North America

12 August 2017

1 reference

12 August 2017

32

1 reference

12 August 2017

133-145

1 reference

12 August 2017

2

1 reference

Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years

12 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

The value of a second transurethral resection in evaluating patients with bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Risk factors in carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Significance of random bladder biopsies in superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Clinical evaluation of random biopsy of urinary bladder in patients with superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Clinical significance of denuded urothelium in bladder biopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: A new proposal.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Multivariate analysis of the prognostic factors of primary superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Correlation between p53 over expression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

p53 Expression Predicts Progression and Poor Survival in T1 Bladder Tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Accumulation of nuclear p53 and tumor progression in bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

p53 immunoreactivity in biopsy specimens of T1G3 transitional cell carcinoma of the bladder--a helpful parameter in guiding the decision for or against cystectomy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Improved patient outcomes with BCG immunotherapy vs. chemotherapy - Swedish and worldwide experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Role of a bacillus Calmette-Guérin fibronectin attachment protein in BCG-induced antitumor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Dissecting the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Natural history and treatment of low and high risk superficial bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Results of 6 Weekly Intravesical Bacillus Calmette-Guerin Instillations on the Treatment of Superficial Bladder Tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Treatment of superficial bladder cancer with intravesical chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary ca

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette-Guérin (Danish 1331 strain).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

The management of T1G3 bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Defining bacillus Calmette-Guerin refractory superficial bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Superficial bladder cancer: the role of interferon-alpha.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Organ-sparing treatment of advanced bladder cancer: a 10-year experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Radiotherapy is an effective treatment for high-risk T1-bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

The treated natural history of high risk superficial bladder cancer: 15-year outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

T1G3 bladder tumours: the case for radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Identifying distinct classes of bladder carcinoma using microarrays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit, cutaneous or urethral kock pouch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Contemporary management of stage T1 transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Clinical experience with BCG alone versus BCG plus epirubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Pharmacologic effects of paclitaxel in human bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Multicentric Study Comparing Intravesical Chemotherapy Alone and With Local Microwave Hyperthermia for Prophylaxis of Recurrence of Superficial Transitional Cell Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.02.002

10.1016/J.UCL.2005.02.002

7 January 2021

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15862611